Skip to main content

Market Overview

Mainstream Mental Health is Quickly Embracing Psychedelic Drug Therapies

Share:

These days, we can make a very strong case for mind-altering treatments for mental health.

Not only is the US FDA supportive of its use, but countless studies from some of the world's leading companies are showing just how useful it can be, including Silo Wellness (CSE:SILO), Seelos Therapeutics Inc. (NASDAQ: SEEL), Cybin Inc. (NEO:CYBN)(OTC: CLXPF), Mind Medicine Inc. (NEO:MMED)(OTC: MMEDF), and Tryp Therapeutics Inc. (CSE:TRYP).

- A study from JAMA Psychiatry just found that psilocybin "worked better than the usual antidepressant medications," as noted by NPR.

- New York Univ. found "Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreased in cancer-related demoralization and hopelessness, improved spiritual well-being."

- The Beckley Foundation said, "Psilocybin was well-tolerated and induced rapid and lasting reduction in the severity of depressive symptoms."

- The US FDA says psilocybin is a "breakthrough therapy" for clinical depression.

In short, it may only be a matter of time before mind-altering drugs make their way into treatments for mental health. If that happens, the industry could be worth well over $100 billion, as Eight Capital analysts have noted.

Better, according to Wired UK, "Psychedelic medicine will begin to cross over into the mental health mainstream in 2021. In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin – the active substance in magic mushrooms – to treat depression. 2021 will bring new clinical trials, as support for the use of psychedelics in medicine continues to gain momentum."

Look at Silo Wellness (CSE:SILO) for example

Early-mover Silo Wellness' mission is to improve health and wellness through psychedelic medicine to reduce trauma and increase performance by destigmatizing the compounds and making their ingestion easier and more comfortable for the user.

In addition, the company just announced that trading of its common shares has expanded to include overseas listing on the German Börse Frankfurt (FRA) exchange platform. The commons shares of Silo Wellness securities began trading on Friday, April 9, 2021 on the FRA under ticker symbol 3K70 and registered under WKN: A2QQTP and/or ISIN: CA8271241082.

"Expanding our shareholder base more broadly into the European market by commencing trading on the Frankfurt exchange is an important milestone for Silo Wellness as we continue to broaden our international presence," said Douglas K. Gordon, Chief Executive Officer of Silo Wellness.  "By listing on the FRA, a wider audience of investors will now be able to actively participate in the growth of Silo Wellness as we continue to deliver on our mission as well as grow on a global basis."

Other related developments from around the markets include:

Seelos Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced the signing of an agreement between Seelos and AptarGroup, Inc. for the co-exclusive use and supply of Aptar Pharma's Bidose (BDS) Liquid System device for Seelos' intranasal ketamine product candidate, SLS-002, in the investigational development programs for the treatment of suicidality, depression, and Post-Traumatic Stress Disorder (PTSD). Under the terms of the agreement, Seelos has certain rights to add other undisclosed indications to the Strategic Device Partnership.

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as Chief Operating Officer of Cybin US Holdings Inc. The Company also announced that co-founder and former Chief Operating Officer, Paul Glavine will assume the role of Chief Growth Officer of Cybin Inc., and co-founder and former SVP, Business Development, John Kanakis will assume the role of Chief Business Officer.

Mind Medicine Inc., a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific data for predicting responses to MDMA and optimizing dosing. This may maximize the potential beneficial therapeutic effects while reducing adverse responses when treating medical conditions. The study used data from 194 MDMA administrations in ten randomized placebo-controlled studies in healthy subjects conducted by the Liechti Lab at the University Hospital Basel, Switzerland.

Tryp Therapeutics Inc., a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced it has initiated quoting activity on the OTCQB® Venture Market and is eligible for settlement and transfer of its common shares in the United States with The Depository Trust Company. The Company's common shares are currently quoted on the OTCQB under the symbol "TRYPF" and will continue to trade on the Canadian Securities Exchange under the symbol "TRYP". DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. DTC eligibility incorporates an electronic method of clearing securities that accelerates the receipt of stock and cash, reduces costs, and allows the stock to be traded over a much wider selection of brokerage firms by meeting their clearing and settlement requirements.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Silo Wellness has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Silo Wellness. Please click here for full disclaimer.

Contact Information:
2818047972
ty@LifeWaterMedia.com